For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
COVID-19, the disease it causes, surfaced in late 2019, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and Latin America, life in these regions has been upended the way it had been in Asia earlier in the developing crisis. As the coronavirus pandemic has worsened, the entertainment industry has been upended along with most every other facet of life. As experts work toward a better understanding, the world shudders in fear of the unknown, a worry that has rocked global financial markets, leading to daily volatility in the U.S. stock markets.
According to this latest study, the 2020 growth of Pre-Implantation Genetic Diagnosis (PGD) will have significant change from previous year. By the most conservative estimates of global Pre-Implantation Genetic Diagnosis (PGD) market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. We give this scenario a XX% probability, where under the scenario the supply chain will start to recover and quarantines and travel bans will ease, over the Q2. Longer-term, the effect of COVID-19 will be felt throughout the year with some degree of harm done by the virus. Over the next five years the Pre-Implantation Genetic Diagnosis (PGD) market will register a XX% CAGR in terms of revenue, the global market size will reach US$ XX million by 2025.
This report presents a comprehensive overview, market shares, and growth opportunities of Pre-Implantation Genetic Diagnosis (PGD) market by product type, application, key manufacturers and key regions and countries.
This study specially analyses the impact of Covid-19 outbreak on the Pre-Implantation Genetic Diagnosis (PGD), covering the supply chain analysis, impact assessment to the Pre-Implantation Genetic Diagnosis (PGD) market size growth rate in several scenarios, and the measures to be undertaken by Pre-Implantation Genetic Diagnosis (PGD) companies in response to the COVID-19 epidemic.
Segmentation by type: breakdown data from 2015 to 2020 in Section 2.3; and forecast to 2025 in section 10.7.
- Chromosomal Abnormalities
- X-linked Diseases
- Freeze Embryo Testing
- Aneuploidy Screening
- HLA
- Others
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2025 in section 10.8.
- Stem Cell Therapy
- IVF Prognosis
- Late-Onset Genetic Disorders
- Inherited Genetic Disease
- Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
- Roche
- IGENOMIX
- Genea Limited
- Illumina, Inc.
- Natera, Inc.
- Quest Diagnostics
- California Pacific Medical Center (CPMC)
- Cooper Medical, Inc.
- Thermo Fisher Scientific Inc.
- LabCorp
- Reproductive Genetic Innovations
- CombiMatrix
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
- To study and analyze the global Pre-Implantation Genetic Diagnosis (PGD) market size by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
- To understand the structure of Pre-Implantation Genetic Diagnosis (PGD) market by identifying its various subsegments.
- Focuses on the key global Pre-Implantation Genetic Diagnosis (PGD) players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
- To analyze the Pre-Implantation Genetic Diagnosis (PGD) with respect to individual growth trends, future prospects, and their contribution to the total market.
- To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
- To project the size of Pre-Implantation Genetic Diagnosis (PGD) submarkets, with respect to key regions (along with their respective key countries).
- To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
- To strategically profile the key players and comprehensively analyze their growth strategies.